Document Detail


Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
MedLine Citation:
PMID:  21635989     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Prasugrel is the most recent addition to the available thienopyridine antiplatelet agents used to prevent ischemic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
OBJECTIVE: The aim of this article was to review published data on the efficacy and safety profile of prasugrel, cost considerations with its use, and its place in clinical care.
METHODS: We searched PubMed and Ovid databases for English language clinical trial articles, published through December 2010, involving the use of prasugrel in human subjects. The key word prasugrel was used. The review focused on clinical trials, but other articles and Food and Drug Administration documents were also reviewed for relevant information.
RESULTS: Phase II studies showed that prasugrel had a more powerful antiplatelet effect and was more effective in its inhibition of platelet activation than clopidogrel. In the only Phase III trial completed before its Food and Drug Administration approval, prasugrel demonstrated a decrease in the primary composite efficacy end point of the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke relative to clopidogrel (643 [9.9%] vs 781 [12.1%], respectively; P = 0.001). Prasugrel was associated with a significantly higher risk of bleeding compared with clopidogrel. Non-coronary artery bypass graft-related thrombolysis in myocardial infarction (TIMI) major bleeding occurred in 146 (2.4%) patients in the prasugrel group versus 111 (1.8%) patients in the clopidogrel group (P = 0.03). For every 1000 patients treated with prasugrel instead of clopidogrel, a total of 23 myocardial infarctions could be prevented at the cost of 6 additional TIMI major bleeding events. However, this benefit was diminished with longer-term therapy. Adverse outcomes of prasugrel use outweighed its benefits in certain subgroups, including patients >75 years old, those weighing <60 kg, and patients with a history of stroke or transient ischemic attack.
CONCLUSIONS: Prasugrel's clinical benefits were counterbalanced by an increase in bleeding risk compared with conventional thienopyridine treatment with clopidogrel. Current practice guidelines incorporated prasugrel as a treatment option, but at this time do not recommend that prasugrel be selected over clopidogrel in any patient subgroup. Further study is required to determine optimal dosing and proper patient selection with prasugrel treatment.
Authors:
Michelle T Martin; Sarah A Spinler; Edith A Nutescu
Related Documents :
22577429 - Chlamydia pneumoniae infection and cardiac risk factors in patients with myocardial inf...
22343639 - Topographic location of acute pontine infarction is associated with the development of ...
21947989 - Effects of levosimendan without loading dose on systolic and diastolic function in pati...
11951789 - Ace inhibitors in cardiovascular diseases.
3995529 - Computerized echocardiographic study of left ventricular function and cardiodynamic inv...
22917729 - Culprit only or multivessel percutaneous coronary interventions in patients with st-seg...
9134619 - The heart muscle's putative "secondary structure'. functional implications of a band-li...
6878379 - Improved myocardial protection with perfluorocarbon cardioplegia.
15220009 - Prevention and treatment of stroke in patients with hypertension.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical therapeutics     Volume:  33     ISSN:  1879-114X     ISO Abbreviation:  Clin Ther     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-06-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  425-42     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.
Affiliation:
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois; University of Illinois at Chicago Medical Center, Chicago, Illinois.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a pers...
Next Document:  Palonosetron Versus Other 5-HT(3) Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea...